Results 231 to 240 of about 122,680 (303)

Open-Label Placebos as Adjunct for the Preventive Treatment of Migraine: A Randomized Clinical Trial.

JAMA Netw Open
Kleine-Borgmann J, Schmidt K, Ludwig L, Schulz M, Holle-Lee D, Gaul C, Bingel U.   +6 more
europepmc   +1 more source

Calcium sodium phosphosilicate toothpastes impact on the treatment of dentin hypersensitivity: an umbrella review. [PDF]

Saudi Dent J
Ziaaddini S, Riahi N, Majidinia S, Sarraf Shirazi A, Motamedosanaye V, Mostafazadehbakhtiyary M.   +5 more
europepmc   +1 more source

Interleukin (IL)‐5, Eosinophils and IL‐5 Pathway Inhibitors in Eosinophilic Granulomatosis with Polyangiitis.

Arthritis &Rheumatology, Accepted Article.
Alvise Berti, Christian Pagnoux
wiley   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

Placebo rates in randomized clinical trials of ulcerative colitis: an individual patient data meta-analysis [PDF]

Virginia Solitano, Malcolm Hogan, Siddharth Singh, Silvio Danese, Laurent Peyrin-Biroulet, Sudheer K. Vuyyuru, John K MacDonald, Guangyong Zou, Yuhong Yuan, Bruce E. Sands, Remo Panaccione, Brian G. Feagan, Jurij Hanžel, Rocío Sedaño, Parambir Dulai, Neeraj Narula, Christopher Ma, Vipul Jairath   +17 more
openalex   +1 more source

Pregabalin dependence, withdrawal, suicidality and psychosis reports: A disproportionality analysis of the Australian adverse events database

British Journal of Clinical Pharmacology, EarlyView.
Aims Globally, Australia has the highest per capita consumption rate of pregabalin, commonly prescribed for neuropathic pain. Emerging evidence suggests pregabalin may be associated with the onset or recurrence of several potentially life‐threatening psychiatric events in some individuals.
Amy G. McNeilage, Ali Gholamrezaei, Bridin Murnion, Suzanne Nielsen, Claire E. Ashton‐James   +4 more
wiley   +1 more source

How do placebos work?

European Journal of Psychotraumatology, 2018
Fabrizio Benedetti, Alessandro Piedimonte, Elisa Frisaldi   +2 more
doaj   +1 more source

Prescriptions of Essentially Placebo Treatments Among General Practitioners in 21 Countries.

JAMA Netw Open
Wolters F, Peerdeman K, Gussekloo J, Adler L, Asenova R, Kánská PB, Collins C, Dumitra GG, Howick J, Peštic SK, Kurpas D, Lazic V, Lingner H, Mallen CD, Missiou A, Peremans L, Petrazzuoli F, Pilv-Toom L, Poortvliet RKE, Thulesius HO, Torzsa P, Tsopra R, Tkachenko V, Viegas R, Evers AWM, Streit S.   +25 more
europepmc   +1 more source

What are set and setting: Reducing vagueness to improve research and clinical practice. [PDF]

J Psychopharmacol
Patch K, Smith WR.
europepmc   +1 more source

An experimental medicine protocol for exploring the haemodynamic effects of dual agonism at the glucagon‐like peptide‐1 and glucagon receptor in healthy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims Glucagon‐like peptide‐1 (GLP‐1) and glucagon dual receptor agonists are in clinical development for a range of metabolic conditions, including type 2 diabetes and obesity. The cardiovascular actions at these receptors are well studied, but less is known about their combination.
James Goodman, Victoria E. Parker, Carmel M. McEniery, Giovanni Di Stefano, Annette Hubsch, Evangelia Vamvaka, Jo Helmy, Fotini Kaloyirou, Navazh Jalaludeen, Peter Barker, Lutz Jermutus, Joseph Cheriyan, Philip Ambery, Ian B. Wilkinson   +13 more
wiley   +1 more source